LymphedemaV1, France, Analysis, bibRecord, 000659

Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial

Identifieur interne : 000659 ( France/Analysis ); précédent : 000658; suivant : 000660

Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial

Auteurs : Philippe Bernard [France] ; Olivier Chosidow [France] ; Loíc Vaillant [France]

Source :

BMJ [ 0959-8138 ] ; 2002-10-19.

RBID : ISTEX:2E6D5230625CB93343E61E793EF660B8E23C9E76

Abstract

Objective: To assess the efficacy and safety of oral pristinamycin versus intravenous then oral penicillin to treat erysipelas in patients in hospital. Design: Multicentre, parallel group, open labelled, randomised non-inferiority trial. Setting: 22 French hospitals. Participants: 289 adults admitted to hospital with erysipelas. Results: At follow up (day 25-45) the cure rate (primary efficacy end point) for the per protocol populations was 81% (83/102) for pristinamycin and 67% (68/102) for penicillin. The planned interim analysis (global one sided type I error 5%) showed that the one sided 97.06% confidence interval of the observed difference (pristinamycin−penicillin) between cure rates (3.3% to ∞) exceeded the −10% non-inferiority threshold. For the intention to treat populations the cure rate at follow up was 65% (90/138) for pristinamycin and 53% (79/150) for penicillin, with the one sided 97.06% confidence interval of the observed difference between cure rates (1.7% to ∞) exceeding the −10% non-inferiority threshold. That the lower limit of the confidence interval exceeded the -10% threshold and was also >0 supports the hypothesis that pristinamycin is significantly superior at the 5% level. More adverse events related to treatment, as assessed by the investigators, were reported in the pristinamycin group than in the penicillin group. Most adverse events involved the gastrointestinal tract (nausea, vomiting, and diarrhoea) but were minor and usually did not require discontinuation of treatment. Conclusion: Pristinamycin could be an alternative to the standard intravenous then oral penicillin regimen used to treat erysipelas in adults in hospital, with the advantages of oral first line therapy.

Url:

DOI: 10.1136/bmj.325.7369.864

Affiliations:

France
Champagne-Ardenne, Grand Est, Île-de-France
Paris, Reims

Links to Exploration step

ISTEX:2E6D5230625CB93343E61E793EF660B8E23C9E76

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial</title>
<author><name sortKey="Bernard, Philippe" sort="Bernard, Philippe" uniqKey="Bernard P" first="Philippe" last="Bernard">Philippe Bernard</name>
</author>
<author><name sortKey="Chosidow, Olivier" sort="Chosidow, Olivier" uniqKey="Chosidow O" first="Olivier" last="Chosidow">Olivier Chosidow</name>
</author>
<author><name sortKey="Vaillant, Loic" sort="Vaillant, Loic" uniqKey="Vaillant L" first="Loíc" last="Vaillant">Loíc Vaillant</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:2E6D5230625CB93343E61E793EF660B8E23C9E76</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1136/bmj.325.7369.864</idno>
<idno type="url">https://api.istex.fr/document/2E6D5230625CB93343E61E793EF660B8E23C9E76/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001548</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001548</idno>
<idno type="wicri:Area/Istex/Curation">001548</idno>
<idno type="wicri:Area/Istex/Checkpoint">002577</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002577</idno>
<idno type="wicri:doubleKey">0959-8138:2002:Bernard P:oral:pristinamycin:versus</idno>
<idno type="wicri:Area/Main/Merge">009A15</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC129632</idno>
<idno type="RBID">PMC:129632</idno>
<idno type="wicri:Area/Pmc/Corpus">000A97</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000A97</idno>
<idno type="wicri:Area/Pmc/Curation">000A96</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000A96</idno>
<idno type="wicri:Area/Pmc/Checkpoint">003F46</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003F46</idno>
<idno type="wicri:Area/Ncbi/Merge">000B33</idno>
<idno type="wicri:Area/Ncbi/Curation">000B33</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000B33</idno>
<idno type="wicri:doubleKey">0959-8138:2002:Bernard P:oral:pristinamycin:versus</idno>
<idno type="wicri:Area/Main/Merge">009742</idno>
<idno type="wicri:Area/Main/Curation">009634</idno>
<idno type="wicri:Area/Main/Exploration">009634</idno>
<idno type="wicri:Area/France/Extraction">000659</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial</title>
<author><name sortKey="Bernard, Philippe" sort="Bernard, Philippe" uniqKey="Bernard P" first="Philippe" last="Bernard">Philippe Bernard</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Dermatology, Hôpital Robert-Debré, 51092 Reims</wicri:regionArea>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Champagne-Ardenne</region>
<settlement type="city">Reims</settlement>
</placeName>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Chosidow, Olivier" sort="Chosidow, Olivier" uniqKey="Chosidow O" first="Olivier" last="Chosidow">Olivier Chosidow</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Internal Medicine, Hôpital Pitié-Salpêtriére, 75013 Paris</wicri:regionArea>
<placeName><settlement type="city">Paris</settlement>
<region type="région" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vaillant, Loic" sort="Vaillant, Loic" uniqKey="Vaillant L" first="Loíc" last="Vaillant">Loíc Vaillant</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Dermatology, Hôpital Trousseau, 37044 Tours</wicri:regionArea>
<wicri:noRegion>37044 Tours</wicri:noRegion>
<wicri:noRegion>37044 Tours</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">BMJ</title>
<title level="j" type="abbrev">BMJ</title>
<idno type="ISSN">0959-8138</idno>
<idno type="eISSN">1468-5833</idno>
<imprint><publisher>British Medical Journal Publishing Group</publisher>
<date type="published" when="2002-10-19">2002-10-19</date>
<biblScope unit="volume">325</biblScope>
<biblScope unit="issue">7369</biblScope>
<biblScope unit="page" from="864">864</biblScope>
</imprint>
<idno type="ISSN">0959-8138</idno>
</series>
<idno type="istex">2E6D5230625CB93343E61E793EF660B8E23C9E76</idno>
<idno type="DOI">10.1136/bmj.325.7369.864</idno>
<idno type="href">bmj-325-864.pdf</idno>
<idno type="ArticleID">bmj.325.7369.864</idno>
<idno type="PMID">12386036</idno>
<idno type="local">bmj;325/7369/864</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0959-8138</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: To assess the efficacy and safety of oral pristinamycin versus intravenous then oral penicillin to treat erysipelas in patients in hospital. Design: Multicentre, parallel group, open labelled, randomised non-inferiority trial. Setting: 22 French hospitals. Participants: 289 adults admitted to hospital with erysipelas. Results: At follow up (day 25-45) the cure rate (primary efficacy end point) for the per protocol populations was 81% (83/102) for pristinamycin and 67% (68/102) for penicillin. The planned interim analysis (global one sided type I error 5%) showed that the one sided 97.06% confidence interval of the observed difference (pristinamycin−penicillin) between cure rates (3.3% to ∞) exceeded the −10% non-inferiority threshold. For the intention to treat populations the cure rate at follow up was 65% (90/138) for pristinamycin and 53% (79/150) for penicillin, with the one sided 97.06% confidence interval of the observed difference between cure rates (1.7% to ∞) exceeding the −10% non-inferiority threshold. That the lower limit of the confidence interval exceeded the -10% threshold and was also >0 supports the hypothesis that pristinamycin is significantly superior at the 5% level. More adverse events related to treatment, as assessed by the investigators, were reported in the pristinamycin group than in the penicillin group. Most adverse events involved the gastrointestinal tract (nausea, vomiting, and diarrhoea) but were minor and usually did not require discontinuation of treatment. Conclusion: Pristinamycin could be an alternative to the standard intravenous then oral penicillin regimen used to treat erysipelas in adults in hospital, with the advantages of oral first line therapy.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Champagne-Ardenne</li>
<li>Grand Est</li>
<li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
<li>Reims</li>
</settlement>
</list>
<tree><country name="France"><region name="Grand Est"><name sortKey="Bernard, Philippe" sort="Bernard, Philippe" uniqKey="Bernard P" first="Philippe" last="Bernard">Philippe Bernard</name>
</region>
<name sortKey="Chosidow, Olivier" sort="Chosidow, Olivier" uniqKey="Chosidow O" first="Olivier" last="Chosidow">Olivier Chosidow</name>
<name sortKey="Vaillant, Loic" sort="Vaillant, Loic" uniqKey="Vaillant L" first="Loíc" last="Vaillant">Loíc Vaillant</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000659 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000659 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     ISTEX:2E6D5230625CB93343E61E793EF660B8E23C9E76
   |texte=   Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

Serveur d'exploration sur le lymphœdème

Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial

Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.